Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR Engineered PBMC and PBSC in Multiple Myeloma
NCT03506802Phase 1Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2018
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NY-ESO-1 T-cell receptor-engineered peripheral blood stem cells and mipetresgene autoleucel in multiple myeloma (MM), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Incidence of dose limiting toxicity at 90 days. Planned start Jul 2018; status: withdrawn.
02
Drugs
NY-ESO-1 T-cell receptor-engineered peripheral blood stem cellsmipetresgene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03506802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506802.